core growth come bit short
dx ep beat opex control
report rev y/i estimate
guidanc consensu organ sale growth vs
estimate guid diagnost dx segment came below-expect
company-specif issu fx sale vs estimate
adj gm vs estimate adj opm expand y/i
vs estimate driven sg cost save adj ep ahead larg
opm beat although tax-rat vs estimate
time issu dx bite carry-ov
primari differ vs expect came pki dx segment tie
consolid genom test lab busi one facil requir
down-tim restart work lower appli genom busi time given
tough comp prior year factor somewhat anticip
magnitud durat impact larger expect like carri
end year result fy core sale guid vs prior
although adj ep guid rais opm gain sg cost control
growth driver still expect kick-in lt view
beyond move piec rest call focus ramif
long-term sale growth acceler margin profil management defer
set hard target tone futur growth driver remain posit
includ vanadi appli genom cannabi test recent acquisit like
cisbio meizheng food safeti test busi china acquir
overal result ytd may somewhat prior expect term
revenu growth continu see path higher growth come year
updat estim sale ep
lower revenu estimate ep estim move
given offset margin improv reiter buy rate po
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart waltham massachusett
found diversifi
provid scientif instrument consum
servic address basic appli
research well signific global health
safeti issu includ matern fetal health
food safeti environment monitor today
compani oper two segment
environment
diversifi provid
scientif instrument consum servic
think compani tact piec
togeth numer acquir asset sinc
form uniqu comprehens solut
custom nich market posit
portfolio transform improv
growth profil see continu tailwind
po base ep estim in-lin compani
broader lst diagnost peer group multipl signific premium
histor multipl due improv core growth margin think
multipl appropri given on-going oper improv improv
growth profil compani
upsid risk po better expect organ sale growth margin
expans faster uptak new product capit deploy option
acquisit compani
downsid risk competit execut integr risk weaker macro
environ fx swing fund cut slower expect uptak new
product regulatori risk reiter neutral rate
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
